← Leaderboards
Hernan Valdez
Case Western Reserve University
$228,499
Attributed
$228,499
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$228,499 · 3
By mechanism
K23$209,300 · 1
M01$19,199 · 2
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Bingcheng Wang$12,028,840
- Thomas T Egelhoff$5,841,046
- James Morley Anderson$9,558,655
- Brian A Cobb$14,802,578
- Ravi V Bellamkonda$14,562,299
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchFlow CytometryAids TherapyHelper T LymphocyteHiv InfectionsT LymphocyteAntiviral AgentsCd4 MoleculeCd8 MoleculeCell ProliferationHost Organism InteractionHuman Immunodeficiency Virus 1Human Therapy EvaluationImmunopathologyLeukocyte CountLymphocyte ProliferationImmunoregulationImmunotherapyHormone TherapyLeukocyte Adhesion MoleculesPrednisoneCell MigrationCell Cycle
Grant awards (8)
Augmenting Immune Restoration in HIV-infected Patients$83,480
K23 · FY2002 · AI
T LYMPHOCYTE SYNTHESIS IN HIV INFECTED PATIENTS$0
M01 · FY2002 · RR
Virologic success &immunologic failure after antiretrov$0
M01 · FY2002 · RR
Augmenting Immune Restoration in HIV-infected Patients$125,820
K23 · FY2001 · AI
Virologic success &immunologic failure after antiretrov$0
M01 · FY2001 · RR
T LYMPHOCYTE SYNTHESIS IN HIV INFECTED PATIENTS$0
M01 · FY2001 · RR
T LYMPHOCYTE SYNTHESIS IN HIV INFECTED PATIENTS$19,199
M01 · FY2000 · RR
Virologic success &immunologic failure after antiretrov$0
M01 · FY2000 · RR